Inhalon Biopharma

Inhaled Immunotherapy for Acute Respiratory Infections

Latest News

July 22, 2021 

Inhalon Collaborates with Celltrion, Inc. to Develop Nebulized Form of Regdanvimab to Treat COVID-19 Patients at Home   Read more

July 16, 2021 

Inhalon Biopharma Appoints Jeff Hutchins, Ph.D. as Chief Development Officer   Read more

May 26, 2021 

Inhalon Biopharma Receives $7 Million from USAMRDC to Study Inhaled “Muco-Trapping” Antibody for the Treatment of COVID-19   Read more

Recent Publications

Challenges and opportunities for antiviral monoclonal antibodies as COVID-19 therapy 

Cruz-Teran C, Tiruthani K, McSweeney M, Ma A, Pickles R Lai SK, Advanced Drug Delivery Reviews, Feb 2021.